

Minutes of the HPRA Leadership Team

Licensing and regulation section

- Friday 26 September 2025 at 9.30am
- Hybrid Teams call and CEO's meeting room 3rd floor

Chair	Present	Apologies
Dr L. Nolan, Chief Executive	Ms E. Stuart, Director of Human Resources and Development	Mr S. d'Art, Director of ICT and Business Services
	Dr N. MacAleenan, Director of Medical Devices	
	Ms S. Curran, Director of Human Products Monitoring	
	Dr D. Murphy, Director of Veterinary Science	
	Dr F. Lonsdale, Director of Human Medicines	
	Ms G. Power, Director of Compliance	
	Ms R. Purcell, Deputy Chief Executive	

Minutes taken by Minutes taken by Ms K. Murphy, Secretary to the Committees
Please note that certain information, such as personal data, confidential/commercially sensitive information, and pending prosecutions may have been removed from these minutes.

*Approved via written procedure

**Attended part of the meeting

1 ADOPTION OF THE AGENDA

The meeting adopted the agenda.

2 DECLARATIONS OF INTEREST

There was nothing to report.

3 ADOPTION OF THE MINUTES OF THE LAST MEETING

The minutes of the meeting of 19 September 2025 were adopted and signed.

4 MATTERS ARISING

4.1 Compliance notice

A further update was provided on the recent issuing of a compliance notice.

5 PUBLIC HEALTH ISSUES

5.1 Paracetamol

The HPRA statement on the use of paracetamol medicines during pregnancy was noted.

6 PRODUCT ISSUES

There was nothing to report.

7 REJECTIONS, SUSPENSIONS AND REVOCATIONS

There was nothing to report.

8 LICENSING TABLES

The relevant tables submitted were approved.

9 AOB

9.1 Sodium Valproate inquiry

Next steps in the HPRA's submission to the sodium valproate inquiry were noted.